LSL Pharma Group Inc. (TSXV:LSL)
Canada · Delayed Price · Currency is CAD 0.3500
-0.0050 (-1.41%)
At close: Aug 10, 2026
LSL Pharma Group Revenue
In the year 2025, LSL Pharma Group had annual revenue of 28.74M CAD with 61.96% growth. LSL Pharma Group had revenue of 7.33M in the quarter ending December 31, 2025, with 36.03% growth.
Revenue
28.74M
Revenue Growth
+61.96%
P/S Ratio
1.57
Revenue / Employee
117.32K
Employees
245
Market Cap
44.99M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 28.74M | 11.00M | 61.96% |
| Dec 31, 2024 | 17.75M | 7.72M | 76.98% |
| Dec 31, 2023 | 10.03M | 1.81M | 22.08% |
| Dec 31, 2022 | 8.21M | -557.15K | -6.35% |
| Dec 31, 2021 | 8.77M | -1.28M | -12.70% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Oct 3, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Planet 13 Holdings | 134.62M |
| Decibel Cannabis Company | 121.32M |
| Vext Science | 72.54M |
| Rubicon Organics | 60.76M |
| C21 Investments | 45.53M |
| MediPharm Labs | 43.28M |
| ZYUS Life Sciences | 413.00K |
| Optimi Health | 231.86K |